Abstract
We read with great interest the recent article by Wang et al.1 reporting on a psoriatic patient co‐affected by HIV‐related Kaposi's sarcoma (KS), whose poorly controlled psoriasis was successfully treated with ustekinumab, a fully monoclonal antibody that targets the common p40 subunit shared by interleukins (IL)‐12 and IL‐23. Interestingly, despite the evidences supporting the role of IL‐12 in inhibiting tumorigenesis,2 the authors reported no KS progression after a 16‐month follow‐up.
This article is protected by copyright. All rights reserved.
http://bit.ly/2TltEjC
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου